Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03080545 · ClinicalTrials.gov registry record · Phase 4
Enstilar in Combination With Biologic Agents
A Phase 4 study, sponsored by Psoriasis Treatment Center of Central New Jersey.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT03080545 is a Phase 4 study that has completed, run by Psoriasis Treatment Center of Central New Jersey. The registered enrollment target is 25 participants.
The verdict
NCT03080545, a Phase 4 study, has completed, sponsored by Psoriasis Treatment Center of Central New Jersey.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
Patients receiving biologic therapy with 5% or less body surface area will receive Enstilar topical foam for 16 weeks.
Interventions
- DRUG Enstilar 0.005%-0.064% Topical Foam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2017-10-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03080545
The ClinicalTrials.gov registry entry for NCT03080545 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Psoriasis Treatment Center of Central New Jersey, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enstilar 0.005%-0.064% Topical Foam is the first listed.
NCT03080545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03080545 about?
NCT03080545 is a clinical study titled "Enstilar in Combination With Biologic Agents". Patients receiving biologic therapy with 5% or less body surface area will receive Enstilar topical foam for 16 weeks.
What is the current status of trial NCT03080545?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2017-05-01. Estimated completion is 2017-10-30.
What interventions are being tested in trial NCT03080545?
The interventions under investigation include: Enstilar 0.005%-0.064% Topical Foam (DRUG).
Who is sponsoring clinical trial NCT03080545?
This trial is sponsored by Psoriasis Treatment Center of Central New Jersey, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.